Important Safety Information

HIV Treatment
Considerations
DHHS Guidelines:
Weight Patients at Risk:
Weight Real-World Data:
INSTI vs PI Patient POV DHHS Guidelines:
Rapid Initiation Patients at Risk:
HGBR M184V/I Prevalence
Efficacy
Treatment-Naïve
Patients Rapid Initiation
Patients Virologically
Suppressed Patients
Resistance
Summary
Safety &
Tolerability
Adverse Event
Profile GI Tolerability Weight Change Real-World Data:
SYMTUZA^® vs
BIC/FTC/TAF Neuropsychiatric
Tolerability Patient Satisfaction
Dosing &
Administration
Dosing Patient Satisfaction STR Pill Guide Coadministration Darunavir Dosing
Simplified
Support & Treatment
Resources
Resources SYMply Start^®CoverMyMeds^®Request
Samples Coverage in
Your Area Switch DRV Patients
to SYMTUZA^®
Important Safety Information
Patient Site
Prescribing Information
Stay Connected

Distributed by: Janssen Therapeutics, Division of Janssen Products, LP, a Johnson & Johnson company, Titusville, NJ 08560

No footer content fetched

Last Updated April 2024

Last Updated April 2024

No footer links content fetched